DDInter593 DDInter1676
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Doxepin {u} (Compound) resembles {v} (Compound) Thiothixene
Doxepin {u} (Compound) resembles {v} (Compound) Imipramine
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Doxepin {u} may lead to a major life threatening interaction when taken with {v} Cyclobenzaprine
Doxepin {u} (Compound) binds {v} (Gene) HTR2A
Doxepin {u} (Compound) upregulates {v} (Gene) MCOLN1
Doxepin {u} (Compound) palliates {v} (Disease) atopic dermatitis
Doxepin {u} (Compound) downregulates {v} (Gene) FAM69A
Doxepin {u} (Compound) causes {v} (Side Effect) Elevated mood
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Doxepin (Compound) resembles Thiothixene (Compound)
Doxepin (Compound) resembles Imipramine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine
Doxepin (Compound) binds HTR2A (Gene)
Doxepin (Compound) upregulates MCOLN1 (Gene)
Doxepin (Compound) palliates atopic dermatitis (Disease)
Doxepin (Compound) downregulates FAM69A (Gene)
Doxepin (Compound) causes Elevated mood (Side Effect)